We found that NR2E1 binds to enhancers to regulate FOXO3 expression, while in other GBM patients lacking ecNR2E1, the enhancers bound by NR2E1 remain inactive in malignant cells (Fig. 5g). This evidence concerns the gene NR2E1 and glioblastoma.